keyword
MENU ▼
Read by QxMD icon Read
search

oral antineoplastic

keyword
https://www.readbyqxmd.com/read/27898360/novel-oral-administrated-paclitaxel-micelles-with-enhanced-bioavailability-and-antitumor-efficacy-for-resistant-breast-cancer
#1
Ting Zhang, Jingwen Luo, Yao Fu, Hanmei Li, Rui Ding, Tao Gong, Zhirong Zhang
Paclitaxel (PTX) is a widely used antineoplastic drug in clinic. Due to poor aqueous solubility, it is administrated by intravenous infusion of cremophor EL containing formulation with serious adverse effects. The low oral bioavailability is a great challenge for oral formulation development. In addition, P-gp mediated multidrug resistance limit its clinical use in various resistant cancers. In this study, a novel super-antiresistant PTX micelle formulation for oral administration was developed. A P-gp inhibitor, bromotetrandrine (W198) was co-encapsulated in the micelle...
November 21, 2016: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/27874243/uhplc-esi-ms-ms-and-pharmacokinetic-analysis-of-justicidin-b-and-6-hydroxy-justicidin-c-in-rats
#2
Jiaoyang Luo, Yichen Hu, Jia'an Qin, Meihua Yang
Arylnaphthalene lignans have attracted considerable interest with the discovery of their antineoplastic activities. Two such compounds are justicidin B and 6'-hydroxy justicidin C, both of which have been isolated from the herb Justicia procumbens. We sought to develop and validate a sensitive and accurate, ultra high performance liquid chromatography with electrospray ionization tandem mass spectrometry method for the structural determination and pharmacokinetics of justicidin B and 6'-hydroxy justicidin C...
November 22, 2016: Journal of Separation Science
https://www.readbyqxmd.com/read/27837044/development-of-a-systematic-approach-to-pharmaceutical-industry-s-patient-assistance-programs-on-accessing-unfunded-cancer-drugs
#3
Victoria Kletas, Mario de Lemos
BACKGROUND: New oncology drugs usually become commercially available several months before the funding decisions are made by provincial public payers. Increasingly, patient assistance programs are being set up by pharmaceutical companies in order to facilitate access of their new cancer drugs before public funding decisions are finalized. We discovered that there is a need to keep this information up to date and available in a central repository, thus we have created a centralized patient assistance chart for use by all who require information on accessing unfunded drugs in our province...
November 10, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27805254/effect-of-a-novel-oral-chemotherapeutic-agent-containing-a-combination-of-trifluridine-tipiracil-and-the-novel-triple-angiokinase-inhibitor-nintedanib-on-human-colorectal-cancer-xenografts
#4
Norihiko Suzuki, Fumio Nakagawa, Kazuaki Matsuoka, Teiji Takechi
Trifluridine/tipiracil (TFTD) is a combination drug that is used for the treatment of metastatic colorectal cancer and was formerly known as TAS-102. It is a combination of two active pharmaceutical compounds, trifluridine, an antineoplastic thymidine-based nucleoside analog, and tipiracil, which enhances the bioavailability of trifluridine in vivo. TFTD is used for the treatment of patients with unresectable advanced or recurrent colorectal cancer that is resistant to standard therapies. In the present study, the anticancer effects of trifluridine in combination with nintedanib, an oral triple angiokinase inhibitor, on human colorectal cancer cell lines were investigated...
October 27, 2016: Oncology Reports
https://www.readbyqxmd.com/read/27793950/phase-i-study-of-the-pan-pi3k-inhibitor-buparlisib-in-adult-chinese-patients-with-advanced-solid-tumors
#5
Yi-Long Wu, L I Zhang, Lucia Trandafir, Tuochuan Dong, Vincent Duval, Katharine Hazell, Binghe Xu
BACKGROUND/AIM: The phosphatidylinositol-3-kinase (PI3K) signaling pathway is frequently activated in cancer. Buparlisib (BKM120), an oral pan-PI3K inhibitor, inhibits proliferation of human cancer in preclinical models. Studies of buparlisib in Western and Japanese adults with advanced solid tumors established a recommended dose of 100 mg/day and showed an acceptable safety profile and evidence of efficacy. This phase I dose-escalation/expansion study aimed to establish the maximum tolerated dose (MTD) of single-agent, once daily oral buparlisib in Chinese patients with advanced solid tumors...
November 2016: Anticancer Research
https://www.readbyqxmd.com/read/27779366/immunohistochemical-expression-of-mdr1-pgp-170-in-canine-cutaneous-and-oral-melanomas-pattern-of-expression-and-association-with-tumour-location-and-phenotype
#6
R Finotello, J M Monné Rodriguez, M Vilafranca, J Altimira, G A Ramirez, A Haines, L Ressel
Canine melanoma (CMM) more commonly affects the oral mucosa and the cutis. CMM shares several features with human melanomas (HMM), included resistance to a broad variety of antineoplastic chemotherapy agents. P-glycoprotein 1 (Pgp) expression is a well-recognized feature of multi-drug resistance and the purpose of this study was to investigate its expression in treatment naïve CMM. We also investigated Pgp association with tumour location and histological features. Histology records of CMM were retrieved, including patients from 2012-2014...
October 25, 2016: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/27737450/drug-drug-interactions-with-oral-antineoplastic-agents
#7
Sandeep Parsad, Mark J Ratain
No abstract text is available yet for this article.
October 13, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27720577/early-use-of-chemotherapy-in-metastatic-prostate-cancer
#8
Mark C Markowski, Michael A Carducci
Since 2010, five new antineoplastic therapies have been FDA approved for the treatment of metastatic prostate cancer. With additional treatment options, questions arose about the optimal sequence of these agents. Until recently, chemotherapy has been deferred until later in the disease course in favor of next-generation androgen deprivation therapy. Prior to the development of abiraterone acetate and enzalutamide, clinical trials were opened investigating the combination of chemotherapy with androgen deprivation therapy in patients with metastatic hormone-sensitive disease...
October 3, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27685528/the-effect-of-%C3%AF-fatty-acids-on-mrna-expression-level-of-ppar%C3%AE-in-patients-with-gastric-adenocarcinoma
#9
A Hosseinzadeh, M-H Somi, H Dolatkhah, A Esfahani, H S Kafil, S M Ardebili
BACKGROUND: The antineoplastic role of peroxisome proliferator-activated receptor gamma (PPARγ) ligandshas previously been demonstrated in several gastric cancer cell lines. Activation of PPARγ by polyunsaturated fatty acids (PUFAs) inhibits growth and proliferationof tumor cells. In this double-blind clinical study, we evaluate the effect of PUFAs on PPARγ mRNA expression in patients with gastric adenocarcinoma. MATERIALS AND METHODS: A total of 34 chemotherapy-naive patients diagnosed with gastric adenocarcinoma were enrolled in the present study...
September 2016: Experimental Oncology
https://www.readbyqxmd.com/read/27658889/grape-seed-procyanidin-extract-mediates-antineoplastic-effects-against-lung-cancer-via-modulations-of-prostacyclin-and-15-hete-eicosanoid-pathways
#10
Jenny T Mao, Jane Smoake, Heesung Park, Qing-Yi Lu, Bingye Xue
Grape seed procyanidin extract (GSE) has been reported to exert antineoplastic properties via the inhibition of cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) eicosanoid pathways. In addition, ample data link carcinogenesis to inflammatory events involving other major eicosanoid metabolic pathways, including prostacyclin (PGI2) and 15-Hydroxyeicosatetraenoic acid (15-HETE). We therefore evaluated the effects of GSE on prostacyclin synthase (PTGIS)/PGI2 and 15-lipoxigenase-2 (15-LOX-2)/15-HETE productions by human lung premalignant and malignant cells and correlated the findings with anti-proliferative or pro-apoptotic effects of GSE...
September 22, 2016: Cancer Prevention Research
https://www.readbyqxmd.com/read/27619395/lanreotide-depot-an-antineoplastic-treatment-of-carcinoid-or-neuroendocrine-tumors
#11
Edward M Wolin, Amandine Manon, Christophe Chassaing, Andy Lewis, Laurent Bertocchi, Joel Richard, Alexandria T Phan
PURPOSE: Peptide drugs for antineoplastic therapies usually have low oral bioavailability and short in vivo half-lives, requiring less preferred delivery methods. Lanreotide depot is a sustained-release somatostatin analog (SSA) formulation produced via an innovative peptide self-assembly method. Lanreotide is approved in the USA and Europe to improve progression-free survival (PFS) in patients with unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and also approved in Europe for symptom control in carcinoid syndrome associated with GEP-NETs...
September 13, 2016: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/27618035/polyphenols-and-sunburn
#12
REVIEW
Suzana Saric, Raja K Sivamani
Polyphenols are antioxidant molecules found in many foods such as green tea, chocolate, grape seeds, and wine. Polyphenols have antioxidant, anti-inflammatory, and antineoplastic properties. Growing evidence suggests that polyphenols may be used for the prevention of sunburns as polyphenols decrease the damaging effects of ultraviolet A (UVA) and ultraviolet B (UVB) radiation on the skin. This review was conducted to examine the evidence for use of topically and orally ingested polyphenols in prevention of sunburns...
2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27581595/analysis-of-the-approach-to-risk-management-in-onco-hematology-centers-results-of-a-survey-in-italy
#13
Massimo Farina, Gianni De Paoli, Monica Canciani
PURPOSE: Raccomandazione 14 (Recommendation 14), issued by the Italian Ministry of Health, is aimed at providing requirements for preventing medication errors with antineoplastic drugs. Raccomandazione 14 covers all steps of the process, from supply to administration of therapies with specific conclusive guidance on tools and methods to be adopted for the assessment and management of clinical risk. METHODS: A form and a score system were designed and provided to healthcare professionals for self-assessment of adherence to Raccomandazione 14...
August 29, 2016: Tumori
https://www.readbyqxmd.com/read/27501965/2016-updated-mascc-esmo-consensus-recommendations-emetic-risk-classification-and-evaluation-of-the-emetogenicity-of-antineoplastic-agents
#14
Karin Jordan, Alexandre Chan, Richard J Gralla, Franziska Jahn, Bernardo Rapoport, David Warr, Paul J Hesketh
PURPOSE: Employing the same framework as in previous guideline updates, antineoplastic agents were classified into four emetic risk categories. The classification of the emetogenic level of new antineoplastic agents, especially for the oral drugs, represents an increasing challenge. Accurate reporting of emetogenicity of new antineoplastic agents in the absence of preventive antiemetic treatment is rarely available. METHODS: A systematic search was conducted for drugs approved after 2009 until June 2015 using EMBASE and PubMed...
January 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27491282/prescribing-patterns-of-oral-antineoplastic-therapies-observed-in-the-treatment-of-patients-with-advanced-prostate-cancer-between-2012-and-2014-results-of-an-oncology-emr-analysis
#15
Elisabetta Malangone-Monaco, Kathleen Foley, Helen Varker, Kathleen L Wilson, Scott McKenzie, Lorie Ellis
PURPOSE: The purpose of this study was to examine, using a US electronic medical records (EMR) database, the clinical characteristics and real-world treatment sequences in men with advanced prostate cancer who initiated treatment with abiraterone acetate or enzalutamide. METHODS: This retrospective, observational study evaluated adult male patients with a diagnosis of prostate cancer (International Classification of Diseases, Ninth Revision, Clinical Modification code 185) in the EMR database between July 1, 2011, and March 31, 2014, who had initiated first-line treatment with abiraterone acetate or enzalutamide between September 1, 2012, and March 31, 2014...
August 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27488610/the-in-vivo-antineoplastic-and-therapeutic-efficacy-of-troxerutin-on-rat-preneoplastic-liver-biochemical-histological-and-cellular-aspects
#16
Nisha Susan Thomas, Kiran George, Sivaranjani Arivalagan, Vijay Mani, Aktarul Islam Siddique, Nalini Namasivayam
PURPOSE: Troxerutin (TXER), a trihydroxyethylated derivative of the natural bioflavonoid rutin, abundantly found in tea, various fruits and vegetables, is known to exhibit ample pharmacological properties. In the present investigation, we examined the antineoplastic, therapeutic efficacy and furthermore the possible mechanisms of action of TXER against NAFLD/NASH progression to hepatocarcinogenesis. METHODS: The effect of TXER (12.5, 25 or 50 mg/kg b.w/day) was evaluated on the nitrosodiethylamine (NDEA) model of hepatocarcinogenesis in rats, after 16 weeks of oral treatment, with special focus on liver specific enzymes, xenobiotic metabolizing enzymes, antioxidant status, lipid peroxidation profile, DNA damage, fibrosis, cell proliferation and inflammatory status...
August 3, 2016: European Journal of Nutrition
https://www.readbyqxmd.com/read/27455550/bile-salt-liposomes-for-enhanced-lymphatic-transport-and-oral-bioavailability-of-paclitaxel
#17
Bin Zhang, Aiying Xue, Chen Zhang, Jinlong Yu, Wen Chen, Deqing Sun
Paclitaxel (PTX), a BCS class IV drug that is characterized by its poor solubility and is a substrate for P-glycoprotein, is one of the most widely used antineoplastic agents. However, oral administration of PTX for chemotherapy is highly challenging. The aim of this study was to develop bile-salt liposomes (BS-Lips) to enhance the absorption of PTX and thus improve its therapeutic outcome. The BS-Lips were prepared by the thin-film hydration method and characterized in terms of particle size and morphology...
June 2016: Die Pharmazie
https://www.readbyqxmd.com/read/27401244/baton-crc-a-phase-ii-randomized-trial-comparing-tivozanib-plus-mfolfox6-with-bevacizumab-plus-mfolfox6-in-stage-iv-metastatic-colorectal-cancer
#18
Al B Benson, Igor Kiss, John Bridgewater, Ferry A L M Eskens, Carolyn Sasse, Sandra Vossen, Jihong Chen, Chip Van Sant, Howard A Ball, Anne Keating, Andrew Krivoshik
PURPOSE: Tivozanib, a selective inhibitor of VEGFR-1, -2, and -3, plus mFOLFOX6 in an advanced gastrointestinal cancer phase Ib study had encouraging antineoplastic activity and a tolerable safety profile. This randomized, open-label, phase II trial of tivozanib/mFOLFOX6 versus bevacizumab/mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (mCRC) evaluated tivozanib activity versus bevacizumab. EXPERIMENTAL DESIGN: Treatment-naïve patients received mFOLFOX6 every 2 weeks of each 28-day cycle plus either tivozanib orally 1...
July 11, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27341603/vitamin-d-and-physical-activity-in-patients-with-colorectal-cancer-epidemiological-evidence-and-therapeutic-implications
#19
Vicente Morales-Oyarvide, Jeffrey A Meyerhardt, Kimmie Ng
Colorectal cancer (CRC) is a leading cause of cancer incidence and mortality in the United States. Notwithstanding major improvements in the early detection and treatment of CRC, an important proportion of patients who received a diagnosis of localized disease ultimately have a recurrence and die, underscoring the need of new therapeutic approaches. Vitamin D and physical activity (PA) have emerged as 2 potential interventions for both prevention and treatment of CRC. Plausible biological mechanisms have been described for the antineoplastic effects of vitamin D and PA, and a wealth of epidemiological evidence indicates that 25(OH)D (the main circulating form of vitamin D) and PA levels are inversely associated with CRC risk...
May 2016: Cancer Journal
https://www.readbyqxmd.com/read/27330277/nelfinavir-is-effective-against-human-cervical-cancer-cells-in-vivo-a-potential-treatment-modality-in-resource-limited-settings
#20
Mitzie-Ann Davis, Joe R Delaney, Chandni B Patel, Ryan Storgard, Dwayne G Stupack
OBJECTIVE: The standard treatment for cervical cancer in developed countries includes surgery and chemoradiation, with standard of care lagging in developing countries. Even in the former case, treatment frequently yields recalcitrant tumors and women succumb to disease. Here we examine the impact of nelfinavir, an off-patent viral protease inhibitor, which has shown promise as an antineoplastic agent. METHODS: We evaluated the morphological and proliferative effects of the autophagy-stressing drug nelfinavir in normal and cisplatin-resistant cervical cancer cells...
2016: Drug Design, Development and Therapy
keyword
keyword
86616
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"